Overview

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.
Details
Lead Sponsor:
AstraZeneca
Treatments:
Anastrozole